Brief: Vigil Neuroscience Receives FDA Fast Track Designation For Vgl101 For The Treatment Of Patients With Alsp
01/11/2022 11:15
Nov 1 (Reuters) - Vigil Neuroscience Inc VIGL.O :
* VIGIL NEUROSCIENCE RECEIVES FDA FAST TRACK DESIGNATION FOR
VGL101 FOR THE TREATMENT OF PATIENTS WITH ALSP
Source text for Eikon: ID:nGNX98jJyF
Further company coverage: VIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vigil Neuroscience
See all newsVigil Neuroscience Inc reports results for the quarter ended June 30 - Earnings Summary
Vigil Neuroscience Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
U.S. RESEARCH ROUNDUP-Ralph Lauren, Vigil Neuroscience, Workday
Deals of the day-Mergers and acquisitions